AZN vs NVST

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.